Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR

Experimental Cell Research

Volumn 323, Issue 2, 2014, Pages 288-296

  Hwang, Ki Eun ^a   Kwon, Su Jin ^a   Kim, Young Suk ^a   Park, Do Sim ^b   Kim, Byoung Ryun ^b   Yoon, Kwon Ha ^b   Jeong, Eun Taik ^a   Kim, Hak Ryul ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

EGFR tyrosine kinase inhibitors; Lung cancer; Resistance; Simvastatin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; CASPASE; CYCLIN D1; ERLOTINIB; GEFITINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN; SMALL INTERFERING RNA; SURVIVIN; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; INSULIN TREATMENT; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

EGFR TYROSINE KINASE INHIBITORS; LUNG CANCER; RESISTANCE; SIMVASTATIN;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CATENINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIMVASTATIN;

EID: 84897512977     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.02.026     Document Type: Article

References (39)

1. Engelman J.A., Jänne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14:2895-2899.
2. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
3. Pao W., Miller V.A, Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
4. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., Mcginiis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., Haber D.A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Nat. Acad. Sci. U.S.A. 2005, 102:7665-7670.
5. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.K., Jänne P.A. An irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67:11924-11932.
6. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., Padera R.D., Shapiro G.I., Baum A., Himmelsbach F., Rettiq W.J., Meyerson M., Solca F., Greulich H., Wong K.K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
7. Godin-Heymann N., Ulkus L., Brannigan B.W., McDermott U., Lamb J., Maheswaran S., Settleman J., Haber D.A. The T790M gatekeeper mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 2008, 7:874-879.
8. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
9. Nowakowski G.S., Maurer M.J., Habermann T.M., Ansell S.M., Macon W.R., Ristow K.M., Allmer C., Slager S.L., Witziq T.E., Cerhan J.R. Statin use and prognosis in patients with diffuse large b-cell lymphoma and follicular lymphoma in the rituximab era. J. Clin. Oncol. 2010, 28:412-417.
10. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin. Cancer Res. 2003, 9:10-19.
11. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., Lippman S.M. Statins and cancer prevention. Nat. Rev. Cancer 2005, 5:930-942.
12. Jakobisiak M., Golab J. Potential antitumor effects of statins. Int. J. Oncol. 2003, 23:1055-1069.
13. Hwang K.E., Na K.S., Park D.S., Choi K.H., Kim B.R., Shim H., Jeong E.T., Kim H.R. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest. New Drugs 2011, 29:945-952.
14. Mantha A.J., Hanson J.E., Goss G., Lagarde A.E., Lorimer I.A., Dimitroulakos J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin. Cancer Res. 2005, 11:2398-2407.
15. Dimitroulakos J., Lorimer I.A., Goss G. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res. 2006, 12:4426s-4431s.
16. Zhao T.T., Le Francois G.D., Goss G., Ding K., Bradbury P.A., Dimitroulakos J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 2010, 29:4682-4692.
17. Li F., Ambrosini G., Chu E.Y., Plescia J., Toqnin S., Marchisio P.C., Altiery D.C. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 1998, 396:580-584.
18. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res. 2003, 9:2683-2692.
19. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, 279:34087-34090.
20. Monzó M., Rosell R., Felip E., Astudillo J., Sánchez J.J, Maestre J., Martín C., Font A., Barnadas A., Abad A. Novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 1999, 17:2100-2104.
21. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000, 6:127-134.
22. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001, 23:251-258.
23. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58:5071-5074.
24. Marioni G., Bertolin A., Giacomelli L., Marchese-Ragona R., Savastano M., Calgaro N., Marino F., De Filippis C., Staffieri A. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res. 2006, 26:3813-3817.
25. Osaka E., Suzuki T., Osaka S., Yoshida Y., Sugita H., Asami S., Tabata K., Hemmi A., Sugitani M., Nemoto N., Ryu J. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem. Cytochem. 2006, 39:95-100.
26. Olie R.A., Simões-Wüst A.P., Baumann B., Leech S.H, Fabbro D., Stahel R.A., Zangemeister-Wittke U. A novel antisense oligonuclotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60:2805-2809.
27. Kaneko R., Tsuji N., Asanuma K., Tanabe H., Kobayashi D., Watanabe N. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J. Biol. Chem. 2007, 282:19273-19281.
28. Okamoto K., Okamoto I., Okamoto W., Tanaka K., Takezawa K., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 2007, 70:10402-10410.
29. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschi T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
30. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
31. Fang D., Hawke D., Zheng Y., Xia Y., Meisenhelder J., Nika H., Mills G.B., Kobayashi R., Hunter T., Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem. 2007, 282:11221-11229.
32. Regales L., Gong Y., Shen R., de StanchinaE E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Ouerfelli O., Mellinghoff I.K., Zakowski M.F., Politi K.A., Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutation lung cancer. J. Clin. Invest. 2009, 119:3000-3010.
33. Han J.Y., Lee S.H., Yoo N.J., Hyung L.S., Moon Y.J, YUN T., Kim H.T., Lee J.S. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2011, 17:1553-1560.
34. Janmaat M.L, Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 2006, 118:209-214.
35. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6:1004-1010.
36. Ohashi H., Takagi H., Oh H., Suzuma K., Suzuma I., Miyamoto N., Uemura A., Watanabe D., Murakami T., Sugaya T., Fukamizu A., Honda Y. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ. Res. 2004, 94:785-793.
37. Fornaro M., Plescia J., Chheang S., Tallini G., Zhu Y.M., King M., Altiery D.C., Languino L.R. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT-survivin pathway. J. Biol. Chem. 2003, 278:50402-50411.
38. Chen Y.C., Shen S.C., Lee W.R., Hsu F.L., Lin H.Y., Ko C.H., Tseng S.W. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase-3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol. 2002, 64:1713-1724.
39. Wali V.B., Sylvester P.W. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 2007, 42:1113-1123.